About us Contacts Drug interactions: 390 212
Drug search by name

Pradaxa and Quinidex Extentabs

Determining the interaction of Pradaxa and Quinidex Extentabs and the possibility of their joint administration.

Check result:
Pradaxa <> Quinidex Extentabs
Relevance: 26.08.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

QuiNIDine may increase the blood levels and effects of dabigatran. Combining these medications may increase the risk of anemia and bleeding complications. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Call your doctor promptly if you experience paleness of skin, fatigue, dizziness, fainting, unusual bleeding or bruising, swelling, vomiting, blood in your urine or stools, headache, or weakness during treatment with these medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR: Coadministration with potent inhibitors of P-glycoprotein such as quinidine may significantly increase the bioavailability of dabigatran following oral administration of dabigatran etexilate, which is a substrate of the efflux transporter. In three female study subjects administered dabigatran with 600 mg quinidine sulfate, systemic exposure to dabigatran was approximately twice that expected with dabigatran alone. In another study, administration of dabigatran over 3 days in combination with quinidine (200 mg every 2 hours up to a total dose of 1000 mg) on the third day resulted in a 56% increase in dabigatran peak plasma concentration (Cmax) and a 53% increase in systemic exposure (AUC) compared to administration of dabigatran alone. In a phase 3 clinical trial of dabigatran etexilate for the prevention of stroke and systemic embolism in patients with atrial fibrillation, concomitant administration of quinidine and dabigatran etexilate did not appear to increase the relative risk of bleeding compared to the combination of warfarin and quinidine.

MANAGEMENT: Caution is advised if dabigatran is used in combination with quinidine. Pharmacologic response to dabigatran should be monitored more closely whenever quinidine is added to or withdrawn from therapy, and the dabigatran dosage adjusted as necessary. Patients should be monitored for the development of anemia and bleeding complications during coadministration.

References
  • "Product Information. Pradax (dabigatran)." Boehringer Ingelheim (Canada) Ltd, Burlington, IA.
  • "Product Information. Pradaxa (dabigatran)." Boehringer-Ingelheim, Ridgefield, CT.
  • Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  • Cerner Multum, Inc. "Australian Product Information." O 0
Pradaxa

Generic Name: dabigatran

Brand name: Pradaxa

Synonyms: n.a.

Quinidex Extentabs

Generic Name: quinidine

Brand name: Quin-G, Cardioquin, Quinora, Quinidex Extentabs, Quinaglute Dura-Tabs, Quin-Release

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction